SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies, Inc. (Pink Sheets: OVIT) reported continued strong growth in revenue, in the third quarter of 2009. For the nine months ended, revenues increased to $697,456 up from $249,565 in the prior year period. Net loss per diluted share was $0.22 compared with a loss of $0.32 per diluted share in the prior period.
